Takami Ishizuka

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Top Venues

JMIR research protocols

Neuropsychopharmacology reports

This page only lists publications with an associated author ORCID identifier.

Publications

Tomoko Okamoto, Takami Ishizuka, Reiko Shimizu, Yasuko Asahina, Harumasa Nakamura, Yuko Shimizu, Yoichiro Nishida, Takanori Yokota, Youwei Lin, Wakiro Sato, Takashi Yamamura
Efficacy and Safety of the Natural Killer T Cell-Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial. JMIR research protocols 13 (2024)
Tomoko Okamoto, Takami Ishizuka, Reiko Shimizu, Yasuko Asahina, Harumasa Nakamura, Yuko Shimizu, Yoichiro Nishida, Takanori Yokota, Youwei Lin, Wakiro Sato, Takashi Yamamura
Efficacy and Safety of the Natural Killer T Cell-Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial. JMIR research protocols 13 (2024)
Tomoko Okamoto, Takami Ishizuka, Reiko Shimizu, Yasuko Asahina, Harumasa Nakamura, Yuko Shimizu, Yoichiro Nishida, Takanori Yokota, Youwei Lin, Wakiro Sato, Takashi Yamamura
Efficacy and Safety of the Natural Killer T Cell-Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial. JMIR research protocols 13 (2024)
Tomoko Okamoto, Takami Ishizuka, Reiko Shimizu, Yasuko Asahina, Harumasa Nakamura, Yuko Shimizu, Yoichiro Nishida, Takanori Yokota, Youwei Lin, Wakiro Sato, Takashi Yamamura
Efficacy and Safety of the Natural Killer T Cell-Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial. JMIR research protocols 13 (2024)
Takami Ishizuka, Hirofumi Komaki, Yoshitsugu Aoki, Harumasa Nakamura, Norio Motohashi, Eri Takeshita, Yuko Shimizu-Motohashi, Akihiko Ishiyama, Chihiro Yonee, Shinsuke Maruyama, Eisuke Hida, Yoshitsugu Aoki
Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial. Neuropsychopharmacology reports 43 (2) (2023)